Semin Liver Dis 2015; 35(02): 157-165
DOI: 10.1055/s-0035-1550056
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Fibrosis in the Post-HCV Era

Massimo Pinzani
1   Institute for Liver and Digestive Health, University College London and Sheila Sherlock Liver Centre, Royal Free Hospital, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
14 May 2015 (online)


The introduction of interferon-free regimens for the treatment of chronic hepatitis C virus (HCV) infection represents a key turn in hepatology because of their extremely high therapeutic efficacy and relatively safe use also in “difficult-to-treat” and/or “difficult-to-cure” HCV subgroups, including patients with cirrhosis. Due to treatment guidelines based on health economics, patients with cirrhosis will likely represent the frontline in the use of the new anti-HCV agents. Accordingly, this article concentrates on the effect of sustained viral response (SVR) following antiviral treatment for HCV on the evolution of tissue fibrosis and cirrhosis, and more importantly, on the clinical consequences of viral eradication, particularly in patients in which SVR has been achieved in an advanced stage of the disease. In this context, the assessment of fibrosis regression and possibly of cirrhosis reversal will represent the diagnostic challenge of the next decade.

  • References

  • 1 Miller MH, Agarwal K, Austin A , et al; British Viral Hepatitis group; British Society of Gastroenterology Liver Committee; British Association for the Study of Liver; Scottish Society of Gastroenterology; Scottish Viral Hepatitis group; Scottish Viral Hepatitis Nurses group. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther 2014; 39 (12) 1363-1375
  • 2 Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146 (5) 1176-1192
  • 3 Toy M. Cost-effectiveness of viral hepatitis B & C treatment. Best Pract Res Clin Gastroenterol 2013; 27 (6) 973-985
  • 4 Zeuzem S. Decade in review-HCV: hepatitis C therapy-a fast and competitive race. Nat Rev Gastroenterol Hepatol 2014; ; Epub ahead of print
  • 5 Poynard T, McHutchison J, Manns M , et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5) 1303-1313
  • 6 Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158 (5 Pt 1): 329-337
  • 7 van der Meer AJ, Veldt BJ, Feld JJ , et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24) 2584-2593
  • 8 Veldt BJ, Heathcote EJ, Wedemeyer H , et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147 (10) 677-684
  • 9 Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85 (6) 1019-1027
  • 10 Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005; 21 (6) 653-662
  • 11 Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012; 51 (19) 2745-2747
  • 12 Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Rev Gastroenterol Hepatol 2012; 6 (2) 187-198
  • 13 Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?. Liver Int 2014; 34 (Suppl. 01) 85-90
  • 14 Marcellin P, Gane E, Buti M , et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865) 468-475
  • 15 Chang TT, Liaw YF, Wu SS , et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 (3) 886-893
  • 16 Iredale JP, Benyon RC, Pickering J , et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102 (3) 538-549
  • 17 Krizhanovsky V, Yon M, Dickins RA , et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134 (4) 657-667
  • 18 Troeger JS, Mederacke I, Gwak GY , et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012; 143 (4) 1073-83.e22
  • 19 Kisseleva T, Cong M, Paik Y , et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012; 109 (24) 9448-9453
  • 20 Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14 (3) 181-194
  • 21 Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21 (3) 351-372
  • 22 Issa R, Zhou X, Constandinou CM , et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126 (7) 1795-1808
  • 23 Pellicoro A, Aucott RL, Ramachandran P , et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis. Hepatology 2012; 55 (6) 1965-1975
  • 24 Pellicoro A, Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 (Suppl 1 Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapiesPetro E Petrides and David Brenner) S26
  • 25 Guido M, Mangia A, Faa G ; Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Chronic viral hepatitis: the histology report. Dig Liver Dis 2011; 43 (Suppl. 04) S331-S343
  • 26 Patel K, Nelson DR, Rockey DC , et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6 (2) 242-247
  • 27 Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51 (4) 1445-1449
  • 28 Rosselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013; 62 (9) 1234-1241
  • 29 Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004; 40 (5) 860-867
  • 30 Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46 (5) (Suppl. 05) S186-S196
  • 31 Lemoine M, Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis 2014; 34 (1) 89-97
  • 32 Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: The importance of multi-state models and competing risks analysis. Hepatology 2014;
  • 33 Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56 (5) 1983-1992
  • 34 D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44 (1) 217-231
  • 35 Arvaniti V, D'Amico G, Fede G , et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139 (4) 1246-1256 , 1256.e1–1256.e5
  • 36 Fede G, D'Amico G, Arvaniti V , et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012; 56 (4) 810-818
  • 37 Bruno S, Crosignani A, Facciotto C , et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51 (6) 2069-2076
  • 38 Calvaruso V, Bavetta MG, Ferraro D , et al. Risk of disease decompensation and HCC in patients with HCV cirrhosis nonresponder to PEG IFN plus RBV. Hepatology 2012; 56 (S1): 253A
  • 39 Novo E, Marra F, Zamara E , et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006; 55 (8) 1174-1182
  • 40 Pinzani M, Vizzutti F. Fibrosis and cirrhosis reversibility: clinical features and implications. Clin Liver Dis 2008; 12 (4) 901-913
  • 41 Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50 (3) 604-620
  • 42 D'Amico G, Pasta L, Morabito A , et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014; 39 (10) 1180-1193
  • 43 Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?. Antiviral Res 2014; 107: 23-30
  • 44 Lens S, Mariño Z, Forns X. Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Dig Liver Dis 2014; 46 (Suppl. 05) S197-S205
  • 45 Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014; 28 (5) 771-781
  • 46 McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30 (17) 1969-1983
  • 47 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144 (3) 512-527
  • 48 Coulouarn C, Clément B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol 2014; 60 (6) 1306-1309
  • 49 Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34 (5) 730-739
  • 50 Krawczyk M, Müllenbach R, Weber SN, Zimmer V, Lammert F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat Rev Gastroenterol Hepatol 2010; 7 (12) 669-681
  • 51 Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol 2011; 25 (2) 269-280
  • 52 Patin E, Kutalik Z, Guergnon J , et al; Swiss Hepatitis C Cohort Study Group; International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012; 143 (5) 1244-52.e1 , 12
  • 53 Rüeger S, Bochud PY, Dufour JF , et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 2014;
  • 54 Costentin CE, Trabut JB, Mallet V , et al. Management of hepatitis C virus infection in heavy drinkers. Alcohol Alcohol 2013; 48 (3) 337-342
  • 55 Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 2010; 110 (1-2) 167-171
  • 56 Deltenre P, Louvet A, Lemoine M , et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011; 55 (6) 1187-1194
  • 57 D'Ambrosio R, Aghemo A, Rumi MG , et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56 (2) 532-543
  • 58 Calvaruso V, Burroughs AK, Standish R , et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009; 49 (4) 1236-1244
  • 59 Calvaruso V, Di Marco V, Bavetta MG , et al. Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Aliment Pharmacol Ther 2014;
  • 60 Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12 (12) 1791-1798
  • 61 Vizzutti F, Arena U, Romanelli RG , et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45 (5) 1290-1297
  • 62 Colecchia A, Montrone L, Scaioli E , et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012; 143 (3) 646-654
  • 63 Chen SH, Li YF, Lai HC , et al. Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C. J Viral Hepat 2012; 19 (9) 654-663
  • 64 Hézode C, Castéra L, Roudot-Thoraval F , et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34 (6) 656-663
  • 65 Stasi C, Arena U, Zignego AL , et al. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis 2013; 45 (10) 840-843
  • 66 D'Ambrosio R, Aghemo A, Fraquelli M , et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59 (2) 251-256
  • 67 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008; 5 (2) 95-106
  • 68 Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation?. J Hepatol 2012; 56 (Suppl. 01) S66-S74
  • 69 Hytiroglou P, Snover DC, Alves V , et al. Beyond “cirrhosis”: a proposal from the International Liver Pathology Study Group. Am J Clin Pathol 2012; 137 (1) 5-9